8 results match your criteria Cancer treatment communications[Journal]

  • Page 1 of 1

Rapidly fatal advanced -mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Cancer Treat Commun 2016 5;9:41-43. Epub 2016 Jul 5.

Department of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, USA.

Use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is associated with dramatic, durable, and tolerable responses and side effect profiles when applied for palliation of advanced -mutated non-small-cell lung cancers (NSCLCs). Expert guidelines recommend that mutation testing results should be available within 10 working days of receipt of tumor specimen by the testing laboratory; in circumstances where the tumor specimen needs to be sent to an external laboratory for testing, the sample should be sent within 3 working days of receiving the request for testing. We report here 2 cases, out of 109 mutated (exon 19 deletion or L858R) NSCLCs seen at our institution, experiencing rapid clinical deterioration and death within the window of time prescribed by consensus testing guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2016.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241076PMC
July 2016
61 Reads

Analyzing clinical outcomes in laparoscopic right vs. left colectomy in colon cancer patients using the NSQIP database.

Cancer Treat Commun 2016 ;8:1-4

Department of Surgery, Division of Surgical Oncology, University of Arizona, Tucson, AZ, United States.

Introduction: Optimization of surgical outcomes after colectomy continues to be actively studied, but most studies group right-sided and left-sided colectomies together. The aim of our study was to determine whether the complication rate differs between right-sided and left-sided colectomies for cancer.

Methods: We identified patients who underwent laparoscopic colectomy for colon cancer between 2005 and 2010 in the American College of Surgeons National Surgical Quality Improvement Program database and stratified cases by right and left side. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073865PMC
http://dx.doi.org/10.1016/j.ctrc.2016.03.006DOI Listing
January 2016
30 Reads

ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES.

Cancer Treat Commun 2016;7:43-46

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC 27514; Department of Medicine, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC 27514.

The incidence of breast cancer brain metastasis (BCBM) is increasing due in part to improved management of systemic disease and prolonged survival. Despite this growing population of patients, there exists little consensus for the treatment of HER2-positive BCBM. Lapatinib, the only brain permeable targeted agent for HER2-positive cancer, has demonstrated limited intracranial response rates and little improvement in progression free survival (PFS) for HER-2 positive patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrc.2016.03.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840897PMC
January 2016
11 Reads

Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.

Cancer Treat Commun 2016;7:1-3

University of Florida Department of Medicine, Box 100278, 1600 SW Archer Road, Gainesville, Florida, 32610.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrc.2016.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835819PMC
January 2016
3 Reads

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.

Cancer Treat Commun 2015;4:174-181

Department of Medicine, 330 Brookline Avenue, Boston, MA 02215, USA.

Introduction: Tumor genotyping using single gene assays (SGAs) is standard practice in advanced non-small-cell lung cancer (NSCLC). We evaluated how the introduction of next generation sequencing (NGS) into day-to-day clinical practice altered therapeutic decision-making.

Methods: Clinicopathologic data, tumor genotype, and clinical decisions were retrospectively compiled over 6 months following introduction of NGS assay use at our institution in 82 patient-tumor samples (7 by primary NGS, 22 by sequential SGAs followed by NGS, and 53 by SGAs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrc.2015.10.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653729PMC
January 2015
43 Reads

Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.

Cancer Treat Commun 2015;4:15-18

Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Medical Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, .

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22130896150001
Publisher Site
http://dx.doi.org/10.1016/j.ctrc.2015.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410270PMC
January 2015
50 Reads

Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin.

Cancer Treat Commun 2015;3:28-32

Breast Program, Stefanie Spielman Comprehensive Breast Center, The Ohio State University Comprehensive Cancer Center, USA.

Complete bone marrow infiltration with profound pancytopenia is very uncommon in breast cancer. Bone marrow metastasis can frequently occur following development of metastatic breast cancer. However, bone marrow failure as the herald of this disease is not typically seen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrc.2014.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408922PMC
January 2015
6 Reads

Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma.

Cancer Treat Commun 2014 ;2(2-3):34-47

Dana Farber Cancer Institute, Harvard Medical School, USA.

Aims: To examine patient perspectives on their personal and contextual factors relevant to TDM. The second aim was to describe physician perspectives on the TDM in older adults (≥60 y.o. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrc.2014.08.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278366PMC
January 2014
5 Reads
  • Page 1 of 1